Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN2350 in BAG3 Mutation Associated Dilated Cardiomyopathy
NCT07218887Phase 2Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2025
- Primary completion
- Jan 2032
- Countries
- 4
01
Overview
A Phase 2 trial of ALXN2350 in dilated cardiomyopathy (DCM), sponsored by Alexion Pharmaceuticals. Started Oct 2025; status: recruiting.
02
Drugs
ALXN2350
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT07218887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218887.